A citation-based method for searching scientific literature

Juan Pablo Frias, Michael A Nauck, Joanna Van, Charles Benson, Ross Bray, Xuewei Cui, Zvonko Milicevic, Shweta Urva, Axel Haupt, Deborah A Robins. Diabetes Obes Metab 2020
Times Cited: 57







List of co-cited articles
652 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A Killion, Shu-Chen Lu, Madeline Fort, Yuichiro Yamada, Murielle M Véniant, David J Lloyd. Endocr Rev 2020
28
10

Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction.
John R Ussher, Jonathan E Campbell, Erin E Mulvihill, Laurie L Baggio, Holly E Bates, Brent A McLean, Keshav Gopal, Megan Capozzi, Bernardo Yusta, Xiemin Cao,[...]. Cell Metab 2018
40
7

Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
Lee-Lee Lai, Shireene Ratna Vethakkan, Nik Raihan Nik Mustapha, Sanjiv Mahadeva, Wah-Kheong Chan. Dig Dis Sci 2020
67
5

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Stephen Caldwell, Mitchell L Shiffman, Charles Landis, Bertus Eksteen, Kosh Agarwal, Andrew Muir, Simon Rushbrook,[...]. Hepatology 2019
119
5

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.
Norbert Stefan, Markus Ramsauer, Paul Jordan, Bettina Nowotny, Konstantinos Kantartzis, Jürgen Machann, Jong-Hee Hwang, Peter Nowotny, Sabine Kahl, Jürgen Harreiter,[...]. Lancet Diabetes Endocrinol 2014
68
5

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, Khalid Jamal Farooqui, Manish Kumar Singh, Jasjeet Singh Wasir, Beena Bansal, Parjeet Kaur, Ganesh Jevalikar, Harmendeep Kaur Gill,[...]. Diabetes Care 2018
268
5

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial.
Sabine Kahl, Sofiya Gancheva, Klaus Straßburger, Christian Herder, Jürgen Machann, Hisayuki Katsuyama, Stefan Kabisch, Elena Henkel, Stefan Kopf, Merit Lagerpusch,[...]. Diabetes Care 2020
97
5

Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
Jean-Michel Petit, Jean-Pierre Cercueil, Romaric Loffroy, Damien Denimal, Benjamin Bouillet, Coralie Fourmont, Olivier Chevallier, Laurence Duvillard, Bruno Vergès. J Clin Endocrinol Metab 2017
116
5

Gut hormone polyagonists for the treatment of type 2 diabetes.
Sara J Brandt, Anna Götz, Matthias H Tschöp, Timo D Müller. Peptides 2018
68
5

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis.
Yuya Seko, Taichiro Nishikawa, Atsushi Umemura, Kanji Yamaguchi, Michihisa Moriguchi, Kohichiroh Yasui, Mayumi Kimura, Hiroaki Iijima, Toshio Hashimoto, Yoshio Sumida,[...]. Diabetes Metab Syndr Obes 2018
51
5

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Renata Belfort, Stephen A Harrison, Kenneth Brown, Celia Darland, Joan Finch, Jean Hardies, Bogdan Balas, Amalia Gastaldelli, Fermin Tio, Joseph Pulcini,[...]. N Engl J Med 2006
5

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
Jonathan W Day, Vasily Gelfanov, David Smiley, Paul E Carrington, George Eiermann, Gary Chicchi, Mark D Erion, Jas Gidda, Nancy A Thornberry, Matthias H Tschöp,[...]. Biopolymers 2012
81
5

Stimulation of insulin secretion by gastric inhibitory polypeptide in man.
J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
734
5

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Michael A Nauck, Markus M Heimesaat, Kai Behle, Jens J Holst, Markus S Nauck, Robert Ritzel, Michael Hüfner, Wolff H Schmiegel. J Clin Endocrinol Metab 2002
426
5

Role of Aramchol in steatohepatitis and fibrosis in mice.
Marta Iruarrizaga-Lejarreta, Marta Varela-Rey, David Fernández-Ramos, Ibon Martínez-Arranz, Teresa C Delgado, Jorge Simon, Virginia Gutiérrez-de Juan, Laura delaCruz-Villar, Mikel Azkargorta, José L Lavin,[...]. Hepatol Commun 2017
63
5

FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis.
Alex M DePaoli, Mei Zhou, Daniel D Kaplan, Steven C Hunt, Ted D Adams, R Marc Learned, Hui Tian, Lei Ling. Diabetes 2019
26
11

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Jan W Eriksson, Per Lundkvist, Per-Anders Jansson, Lars Johansson, Mats Kvarnström, Linda Moris, Tasso Miliotis, Gun-Britt Forsberg, Ulf Risérus, Lars Lind,[...]. Diabetologia 2018
173
5

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
Yan-Ling He, William Haynes, Charles D Meyers, Ahmed Amer, Yiming Zhang, Ping Mahling, Anisha E Mendonza, Shenglin Ma, William Chutkow, Eric Bachman. Diabetes Obes Metab 2019
43
6

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.
Kenneth Cusi, Fernando Bril, Diana Barb, David Polidori, Sue Sha, Atalanta Ghosh, Kristin Farrell, Nishanth E Sunny, Srilaxmi Kalavalapalli, Jeremy Pettus,[...]. Diabetes Obes Metab 2019
77
5

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Sunder Mudaliar, Robert R Henry, Arun J Sanyal, Linda Morrow, Hanns-Ulrich Marschall, Mark Kipnes, Luciano Adorini, Cathi I Sciacca, Paul Clopton, Erin Castelloe,[...]. Gastroenterology 2013
612
5

Peptide-based multi-agonists: a new paradigm in metabolic pharmacology.
S J Brandt, T D Müller, R D DiMarchi, M H Tschöp, K Stemmer. J Intern Med 2018
27
11


NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.
Stephen A Harrison, Stephen J Rossi, Angelo H Paredes, James F Trotter, Mustafa R Bashir, Cynthia D Guy, Rajarshi Banerjee, Mark J Jaros, Sandra Owers, Bryan A Baxter,[...]. Hepatology 2020
127
5

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Zobair Younossi, Frank Tacke, Marco Arrese, Barjesh Chander Sharma, Ibrahim Mostafa, Elisabetta Bugianesi, Vincent Wai-Sun Wong, Yusuf Yilmaz, Jacob George, Jiangao Fan,[...]. Hepatology 2019
698
5

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies.
Jonathan D Roth, Barbara L Roland, Rebecca L Cole, James L Trevaskis, Christian Weyer, Joy E Koda, Christen M Anderson, David G Parkes, Alain D Baron. Proc Natl Acad Sci U S A 2008
312
5

Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia.
Tricia M Tan, Benjamin C T Field, Katherine A McCullough, Rachel C Troke, Edward S Chambers, Victoria Salem, Juan Gonzalez Maffe, Kevin C R Baynes, Akila De Silva, Alexander Viardot,[...]. Diabetes 2013
141
5

Targeted estrogen delivery reverses the metabolic syndrome.
Brian Finan, Bin Yang, Nickki Ottaway, Kerstin Stemmer, Timo D Müller, Chun-Xia Yi, Kirk Habegger, Sonja C Schriever, Cristina García-Cáceres, Dhiraj G Kabra,[...]. Nat Med 2012
205
5

Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake.
Jaimini Cegla, Rachel C Troke, Ben Jones, George Tharakan, Julia Kenkre, Katherine A McCullough, Chung Thong Lim, Nassim Parvizi, Mohamed Hussein, Edward S Chambers,[...]. Diabetes 2014
90
5

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Gregory Gaich, Jenny Y Chien, Haoda Fu, Leonard C Glass, Mark A Deeg, William L Holland, Alexei Kharitonenkov, Thomas Bumol, Holger K Schilske, David E Moller. Cell Metab 2013
597
5

Mechanisms of NAFLD development and therapeutic strategies.
Scott L Friedman, Brent A Neuschwander-Tetri, Mary Rinella, Arun J Sanyal. Nat Med 2018
5

Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study.
Preeshila Behary, George Tharakan, Kleopatra Alexiadou, Nicholas Johnson, Nicolai J Wewer Albrechtsen, Julia Kenkre, Joyceline Cuenco, David Hope, Oluwaseun Anyiam, Sirazum Choudhury,[...]. Diabetes Care 2019
50
6


Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study.
Amra Jujić, Naeimeh Atabaki-Pasdar, Peter M Nilsson, Peter Almgren, Liisa Hakaste, Tiinamaija Tuomi, Lisa M Berglund, Paul W Franks, Jens J Holst, Rashmi B Prasad,[...]. Diabetologia 2020
11
27

Targeted pharmacological therapy restores β-cell function for diabetes remission.
Stephan Sachs, Aimée Bastidas-Ponce, Sophie Tritschler, Mostafa Bakhti, Anika Böttcher, Miguel A Sánchez-Garrido, Marta Tarquis-Medina, Maximilian Kleinert, Katrin Fischer, Sigrid Jall,[...]. Nat Metab 2020
41
7

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
John Blundell, Graham Finlayson, Mads Axelsen, Anne Flint, Catherine Gibbons, Trine Kvist, Julie B Hjerpsted. Diabetes Obes Metab 2017
143
5

Advances in oral peptide therapeutics.
Daniel J Drucker. Nat Rev Drug Discov 2020
175
5

The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation.
Florian Kahles, Ana Liberman, Constantin Halim, Matthias Rau, Julia Möllmann, Robert Werner Mertens, Marcia Rückbeil, Irmgard Diepolder, Benedikt Walla, Sebastian Diebold,[...]. Mol Metab 2018
28
10

Discovery, characterization, and clinical development of the glucagon-like peptides.
Daniel J Drucker, Joel F Habener, Jens Juul Holst. J Clin Invest 2017
162
5


Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity.
Carmelo Quarta, Christoffer Clemmensen, Zhimeng Zhu, Bin Yang, Sini S Joseph, Dominik Lutter, Chun-Xia Yi, Elisabeth Graf, Cristina García-Cáceres, Beata Legutko,[...]. Cell Metab 2017
56
5

Comparison of Human and Murine Enteroendocrine Cells by Transcriptomic and Peptidomic Profiling.
Geoffrey P Roberts, Pierre Larraufie, Paul Richards, Richard G Kay, Sam G Galvin, Emily L Miedzybrodzka, Andrew Leiter, H Joyce Li, Leslie L Glass, Marcella K L Ma,[...]. Diabetes 2019
68
5


Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21.
Timo D Müller, Lorraine M Sullivan, Kirk Habegger, Chun-Xia Yi, Dhiraj Kabra, Erin Grant, Nickki Ottaway, Radha Krishna, Jenna Holland, Jazzminn Hembree,[...]. J Pept Sci 2012
117
5

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.
Nikolaos Mentis, Irfan Vardarli, Lars D Köthe, Jens J Holst, Carolyn F Deacon, Michael Theodorakis, Juris J Meier, Michael A Nauck. Diabetes 2011
109
5

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
681
5

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
W Timothy Garvey, Andreas L Birkenfeld, Dror Dicker, Geltrude Mingrone, Sue D Pedersen, Altynai Satylganova, Dorthe Skovgaard, Danny Sugimoto, Camilla Jensen, Ofri Mosenzon. Diabetes Care 2020
36
8

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
D Elahi, M McAloon-Dyke, N K Fukagawa, G S Meneilly, A L Sclater, K L Minaker, J F Habener, D K Andersen. Regul Pept 1994
256
5

Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.
Salvatore Calanna, Mikkel Christensen, Jens J Holst, Blandine Laferrère, Lise L Gluud, Tina Vilsbøll, Filip K Knop. Diabetes Care 2013
99
5

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
Vlad Ratziu, Fréderic Charlotte, Carole Bernhardt, Philippe Giral, Marine Halbron, Gilles Lenaour, Agnès Hartmann-Heurtier, Eric Bruckert, Thierry Poynard. Hepatology 2010
268
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.